Detalhe da pesquisa
1.
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions - a position statement from the ETOP IBCSG Partners Foundation.
Ann Oncol
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648979
2.
Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Ann Oncol
; 33(5): 511-521, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35218887
3.
Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
Ann Oncol
; 33(1): 67-79, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34562610
4.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Ann Oncol
; 33(2): 181-192, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34839016
5.
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Ann Oncol
; 31(12): 1734-1745, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32976938
6.
ESMO Guidance for Reporting Oncology real-World evidence (GROW).
Ann Oncol
; 34(12): 1097-1112, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848160
7.
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Ann Oncol
; 29(1): 200-208, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186353
8.
EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.
Ann Oncol
; 32(11): 1332-1347, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34364998
9.
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
Ann Oncol
; 32(1): 120-121, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33098996
10.
The ESMO guideline strategy: an identity statement and reflections on improvement.
Ann Oncol
; 26 Suppl 5: v1-7, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26314771
11.
Searching for targets for the systemic therapy of mesothelioma.
Ann Oncol
; 26(8): 1649-60, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25722383
12.
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.
Ann Oncol
; 26(8): 1573-88, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25897013
13.
CD74: a new prognostic factor for patients with malignant pleural mesothelioma.
Br J Cancer
; 110(8): 2040-6, 2014 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24594996
14.
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.
Br J Cancer
; 111(2): 413-20, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24983368
15.
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
Ann Oncol
; 25(9): 1681-1690, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24718890
16.
2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.
Ann Oncol
; 25(8): 1475-84, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24669016
17.
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.
Ann Oncol
; 25(8): 1462-74, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24562446
18.
The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO).
Ann Oncol
; 25(1): 9-15, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335854
19.
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).
Ann Oncol
; 30(2): 161-165, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624547
20.
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
ESMO Open
; 8(3): 101576, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37285717